Левоноргестрелвыделяющая внутриматочная система как метод лечения гиперполименореи у женщин с миомой матки

1. Савицкий Г.А. Миома матки (проблемы патогенеза и патогенетической терапии). СПб.: Элби, 2000.
2. Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990–1997. Obstet Gynecol 2002; 99: 229–34.
3. Coutinho EM. Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone. Coutinho EM, Boulanger GA, Goncalves MT. Am J Obstet Gynecol 1986; 155: 761–7.
4. Chavez NF. Medical treatment of uterine fibroids. Chavez NF, Stewart EA. Clin Obstet Gynecol 2001; 44: 372–84.
5. Stovall TG. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Stovall TG, Ling FW, Henry LC, Woodruff MR. Am J Obstet Gynecol 1991; 164: 1420–3.
6. Benagiano G, Kivinen S, Fadini R et al. Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study. Fertil Steril 1996; 66: 223–9.
7. Hubacher D. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002; 57: 120–8.
8. Sivin I. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994; 61: 70–7.
9. Singer A, Ikomi A. Successful treatment of fibroids using an intrauterine progesterone device. Int J Gynecol Obstet 1994; 46: 55.
10. Fong YF. Effect of the levonorgestrel-releasing intrauterine system on uterine myomas in a renal transplant patient. Contraception 1999; 60: 51–3.
11. Starczewski A. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Ginekol Pol 2000; 71: 1221–5.
12. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization, 2000.
13. Higham JM. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 734–9.
14. Murphy AA. Regression of uterine leiomyomata to the antiprogesterone RU486: dose- response effect. Fertil Steril 1995; 64: 187–90.
15. Barrington JW. The levonorgestrel inttrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997; 104: 614–6.
16. Stewart A. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG 2001; 108: 74–86.
17. Fedele L. Levonorgestrel-releasing intrauterine device for the treatment of menometrorrhagia in a woman on hemodialysis. N Engl J Med 1999; 341: 541.
18. Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 2000; 65: 699–702.
19. Pakarinen P. Therapeutic use of the LNG IUS, and counseling. Semin Reprod Med 2001; 19: 365–72.
20. Hurskainen R. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Hurskainen R, Teperi J, Rissanen P et al. Lancet 2001; 357: 273–7.
21. Istre O. Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resection. Fertil Steril 2001; 76: 304–9.
22. Fong YF. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception 1999; 60: 173–5.
23. Fedele L. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel- releasing intrauterine device. Fertil Steril 1997; 68: 426–9.
24. Golan A. GnRH analogues in the treatment of uterine fibroids. Hum Reprod 1996; 11 (Suppl. 3): 33–41.
25. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 1992; 166: 746–51.
26. Vollenhoven BJ. Uterine fibroids: a clinical review/Vollenhoven BJ, Lawrence AS, Healy DL. Br J Obstet Gynaecol 1990; 97: 285–98.
27. Giudice LC. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod 1993; 8: 1796–806.
28. Rutanen EM. mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. Mol Hum Reprod 1997; 3: 749–54.
29. Pekonen F. Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium. J Clin Endocrinol Metab 1992; 75: 660–4.
30. Maruo T. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000; 65: 585–92.
31. Jarvela I. The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum Reprod 1998; 13: 3379–83.
32. Sturridge F. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf 1996; 15: 430–40.

В.А.Григорьева, Э.К.Айламазян, М.А.Тарасова, А.Л.Коротеев, М.Чен

НИИ акушерства и гинекологии им. Д.О.Отта РАМН (Санкт-Петербург), 
Family Health International (CША)